Liver transplantation is widely indicated as a curative treatment for selected patients with hepatocellular carcinoma. However, with recent therapeutic advances, as well as efforts to increase the donor pool, liver transplantation has been carefully expanded to patients with other primary or secondary malignancies in the liver. Cholangiocarcinoma, colorectal and neuroendocrine liver metastases, and hepatic epithelioid haemangioendothelioma are amongst the most relevant new indications. In this review we discuss the fundamental concepts of this ambitious undertaking, as well as the newest indications for liver transplantation, with a special focus on future perspectives within the recently established concept of transplant oncology.
Introduction
Annually, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are diagnosed in 841,000 people and are responsible for 782,000 deaths worldwide. 1 Colorectal cancer is diagnosed in 1.8 million people every year and it is estimated that~50% of these patients will develop colorectal liver metastasis (CRLM). 1, 2 For patients with liver cancer, the surgical removal of the tumour offers the best chance of cure. Unfortunately, only a minor proportion of these patients are candidates for liver resection (LR) mostly because of decompensated liver disease. Liver transplantation (LT) offers a chance of cure given that it removes the tumour with the widest margin, as well as removing the pro-carcinogenic hepatic microenvironment. Transplantation as treatment for unresectable liver cancer has been explored since the early development of LT. 3 The initial experiences with LT for liver cancer were, however, disappointing. [4] [5] [6] The landscape of LT for cancer changed in 1996, when a strict selection criteria for patients was published. 7 Since then, with better patient selection and refinements to operative and postoperative care, LT has become an effective treatment for several hepatic malignancies. Together with other important advances in hepatology and oncology (e.g. new chemotherapies for gastrointestinal cancer; direct-acting antivirals [DAA] for hepatitis C) a new field in medicine has risen: transplant oncology. 8 In this review, we aim to explore the current indications for LT as a treatment for hepatic malignancies, with a special focus on future perspectives within the concept of transplant oncology.
Hepatocellular carcinoma
The treatment of HCC has become multidisciplinary, involving hepatobiliary and transplantation surgery, hepatology, interventional radiology, radiation and medical oncology. Among all possible strategies to treat HCC, LT offers the best chance of cure. 9 Unfortunately, the number of available grafts is insufficient for all potential candidates. For this reason, LT is reserved for patients who will benefit most. Efforts should focus on strategies to better select patients and to increase the number of available grafts.
criteria and with AFP ≤400 ng/ml can achieve satisfactory post-LT outcomes. 13 The hazard ratio (HR) of HCC recurrence for patients with total tumour volume (TTV) ≤115 cm 3 and serum AFP <400 ng/ml was 2.0 (95% CI 1.7-2.4), when compared to patients with TTV >115 cm 3 and serum AFP >400 ng/ml. 14, 15 The "AFP model" uses a scoring system to classify patients by their risk of recurrence based on largest tumour diameter, number of lesions and serum AFP. Patients who have ≤2 points have a lower probability of recurrence and are within the criteria. Among these patients, the 5-year recurrence rate was 14% vs. 48% for those beyond the AFP criteria. 15 The Metroticket 2.0 system applies serum AFP, tumour size and tumour number to determine the risk of HCCrelated death after LT (applying competing-risk analysis). The c-statistic of the model was 0.72, which was superior to previous criteria. 16 Halazun et al. recently published a model incorporating the concept of AFP response during waiting time. The AFP response was defined as the difference between the highest value and the final pre-LT serum AFP. They showed that dynamic changes in AFP during waiting time are valuable tools to identify patients beyond Milan criteria who could have good outcomes after LT. 17 Surrogates of tumour biology Surrogates of tumour biology have been studied with the aim of improving the selection criteria for HCC. Tumoural differentiation has been proposed as a selection criteria for LT. 18, 19 Sapisochin et al. prospectively demonstrated that in the absence of macroscopic vascular invasion, extrahepatic disease, cancer-related symptoms and poor differentiation (the Extended Toronto Criteria) patients can undergo LT with satisfactory results regardless of tumour size and number (Table 1) . 20 Kaido et al. have shown the utility of associating the levels of serum des-γ-carboxy prothrombin (DCP) to size and number of tumours. 21 The Kyoto criteria select patients with a DCP ≤400 mAU/ml, a largest tumour diameter ≤5 cm and ≤10 lesions (Table 1) . Recently, the 5-5-500 criteria (tumour size ≤5 cm, tumour number ≤5, and AFP ≤500 ng/ml) was associated with a 5-year recurrence rate of 7.3% in patients treated with LDLT. 22 The use of 18 F-fluorodeoxyglucose positron-emission tomography/CT ( 18 FDG-PET/CT) has been correlated with HCC recurrence and increasingly used as a tool for patient selection. 23, 24 Further research is still needed to be able to incorporate PET/CT widely into clinical practice.
Key points
Liver transplantation is widely indicated as a curative treatment for selected patients with hepatocellular carcinoma.
Increasing the donor pool, liver transplantation has been carefully expanded to patients with other primary or secondary malignancies in the liver.
Cholangiocarcinoma, colorectal and neuroendocrine liver metastases, and hepatic epithelioid haemangioendothelioma are amongst the most relevant new indications. demonstrated significantly improved post-LT outcomes when restricting LT to patients with a reduction in AFP from >1,000 to <500 ng/ml after LRT.
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In the near future, the assessment of tumour response on pre-LT imaging can be improved with artificial intelligence methods (e.g. radiomics).
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Primary vs. salvage LT The optimal approach for patients who have failed on prior curative treatments for HCC is controversial. In retrospective series, salvage LT and secondary LR had similar outcomes. 36, 37 However, the risk of recurrence after salvage LT may be lower than secondary resection. 38, 39 The decision to treat with secondary resection or salvage LT remains controversial and depends on the availability of organs within each jurisdiction.
Genetic advances in HCC
Profiling the genomic and biological patterns of tumours and correlating them with clinical outcomes is key to better understanding HCC biology. 40 There Table 2 summarises the main biomarkers under research. Genomic expression does not always reflect an immunologically active phenotype in patients with HCC. Thus, a tumour biopsy may not provide all the information necessary for therapeutic decision making. The association of these tumour genetic findings with adjacent normal liver assessment, serum circulating tumour DNA (ctDNA) and the phenotypic expression in metabolites or serum proteins, could potentially identify a more aggressive tumour behaviour, changing the therapeutic indication and selection for transplantation. At this point, this is all hypothetical and further research is needed and ongoing in this area.
LT for HCC: Increasing the donor pool
To support the expansion of LT for patients with HCC without compromising patients without HCC, there is a need to increase the number of available grafts. There is controversial data on the impact that the different types of grafts can have on the outcomes of patients transplanted with HCC.
Use of marginal grafts
The use of marginal grafts (i.e. older donors, donors after cardiac death (DCD), split livers, steatotic grafts or hepatitis C virus (HCV)-infected grafts) is one of the options to increase the donor pool. Marginal grafts have been of particular interest for patients with HCC given that they usually have better liver function than patients listed with decompensated cirrhosis. The use of non-ideal grafts (i.e. "liver that nobody wants") in patients with HCC has been investigated, showing that acceptable outcomes can be achieved. 57 However, this strategy must be approached with caution to avoid putting patients in good general condition at higher risk of post-transplant complications. Initial studies with the use of DCD grafts raised questions about the increased risk of tumoural recurrence due to the potential oncogenic effect of ischaemiareperfusion injury. 58, 59 This concern was not confirmed by subsequent studies. [60] [61] [62] Likewise, the use of grafts from older donors was seen as a risk factor for post-LT HCC recurrence 63 and currently donor age is not by itself a limitation for donation in many centres worldwide. 64, 65 The use of HCVinfected grafts in recipients with HCV has been proven safe. 66, 67 Cotter et al. demonstrated that, in the DAA era, there has been an increase in the utilisation of HCV-viraemic donor livers, including into HCVnegative recipients, with good graft outcomes. 68 
Review
The use of DAAs has changed the landscape of HCV treatment and, annually, less patients with endstage liver disease due to HCV are listed for LT.
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Living donor liver transplantation The most important intervention to increase the donor pool is living donor liver transplantation (LDLT). Initial results on LDLT for HCC indicated an increased risk of recurrence. 75, 76 However, more recent studies did not confirm this finding. In an intention-to-treat analysis, 2 studies have shown similar outcomes between patients who underwent LDLT and those undergoing LT with grafts from brain-death donors (DDLT). 77,78 Goldaracena et al. have shown that LDLT is associated with survival benefit for patients with HCC. In an intention-totreat analysis, patients who had a potential living donor had a 5-year OS rate of 68% compared to 57% in patients without a potential donor. 79 The presence of a potential live donor was a protective factor for death (HR 0.67; 95% CI 0.53-0.86). Despite being an excellent strategy for patients with HCC waiting for a LT, the widespread use of LDLT must be limited to centres that perform high volumes of both advanced hepatobiliary surgery and LT to diminish the risk of complications for the donor. 80 After live donation, the rate of overall postoperative complications is reported to be around 25-30%, with major complications occurring in 9-10% of patients. 80, 81 Donor mortality has also been reported and estimated between 0.1-0.3%.
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LT for HCC: future prospects The future direction of LT for HCC will focus on the identification of patients at higher risk of recurrence to prevent futile transplantation. This selection will likely move away from tumour size and number, and allow for the incorporation of surrogates of tumour biology. The use of imaging methods such as 18 FDG-PET/CT or genomic technics that could identify circulating DNA or singlecell RNA as a genetic signature of recurrence may improve our current criteria for patient selection. Radiomics applied to pre-treatment imaging assessments may enable clinicians to predict tumour behaviour in the near future. Xu et al. have demonstrated its ability to identify the presence of microvascular invasion in 495 patients with resected HCC. 35 In the context of LT, neoadjuvant therapies may also increase access to transplantation for patients who are currently not candidates. An example of this approach would be patients with macrovascular invasion who respond to neoadjuvant therapies and have a stable period of observation. 84 This should only be done under investigational protocols at this time.
Cholangiocarcinoma
Cholangiocarcinoma represented 2% of all LTs performed for malignancies in Europe between 1988-2016. 85 Hilar CCA (hCCA) and intrahepatic CCA (iCCA) have distinct molecular pathogenesis and biological behaviour and therefore are presented here as separated entities.
LT for CCA: initial experience
The initial experience with LT for CCA was disappointing. In 1988, the group from Kings College published a series of 93 patients who underwent LT for several malignancies of whom 26 had CCA (13 hilar and 13 intrahepatic). 86 The 5-year OS rate for this cohort was 10%. 86 In 1997, Pichlmayr et al. published a series of 24 patients with iCCA and 28 with hCCA who underwent LT. 87 The 5-year OS rates were 0% and 18% for patients with iCCA and hCCA, respectively. 87 This poor initial experience was explained mainly by the lack of criteria for patient selection and the absence of standardised pre-and postoperative treatment.
LT for hCCA
The first study with a strict patient selection and a neoadjuvant therapy protocol was published in 2000 by De Vreede et al.. 88 The so-called Mayo protocol consists of neoadjuvant treatment with 5-fluoracil (for radiosensitisation) and oral capecitabine (maintenance therapy) until LT is performed with preoperative external beam radiation therapy and local brachytherapy. 89 Gemcitabine along with capecitabine are applied in the neoadjuvant protocol in other centres. 90 The effectiveness of LT for hCCA was validated in North America by a study reporting on data from 12 US centres, including 287 patients who underwent LT, in which a 5-year DFS rate of 65% was achieved. 91 Mantel et al. have assessed the results of LT for hCCA in a cohort from the European Liver and Intestine Transplant Association (ELITA) and showed a 5-year OS rate of 59%. 92 After these satisfactory results, hCCA became an indication in many jurisdictions worldwide. [93] [94] [95] [96] [97] The use of LT for patients with locally advanced hCCA and a low preoperative probability of achieving complete resection (e.g. tumours >3 cm and/or with ipsilateral intrahepatic portal branch invasion and/or positive lymph nodes) has been the topic of debate. One small retrospective study (13 patients in the LT group and 7 patients in the resection group) has shown superior results for LT. 98 The group from Nagoya published a series of 216 patients with type IV hCCA who were treated by resection. 99 The 5-year OS rate was 53% among those patients without lymph nodal metastasis. 99 The authors argue that this OS rate is comparable to that seen after LT for hCCA; but, unfortunately, this study did not have an LT group for comparison. 109 The use of neoadjuvant therapies to convert unresectable patients might be preferable to LT in light of organ scarcity. However, even though some patients could be successfully downstaged for resection, it would be fair to offer LT to patients who remained unresectable in the absence of disease progression during neoadjuvant treatment. Therefore, future studies assessing neoadjuvant therapies for advanced iCCA should aim both to downstage patients for resection and to select patients for LT.
LT for CCA: future perspectives A better assessment of patients that have aggressive tumoural biology or extrahepatic disease is key to avoid futile transplantation. For example, the presence of positive circulating tumoural DNA seems to be related to prognosis. 110 Genetic sequencing is also a very important tool in selecting patients with a lower likelihood of recurrence. Mutations in KRAS, BAP1 and CDKN2A are related to a higher probability of recurrence, while mutations in FGFR2 are related to more indolent phenotype. [111] [112] [113] In hCCA, mutations in P53, BRCA1, BRCA2 and PIK3CA are related to a worse prognosis. 111, 112 Whether these genetic profiles will be applied as a selection tool in LT for CCA is still under investigation and cannot be recommended. The future of CCA treatment lies in the development of specific drugs directly targeting pathways of carcinogenesis. Several biomarkers are being studied, opening up opportunities for translational research initiatives in CCA. It is increasingly evident that the CCA desmoplastic microenvironment plays an important role in cancer cell development, and strategies targeting the tumour stroma in combination with the CCA cancer cell will present new diagnostic and therapeutic perspectives. 
Colorectal liver metastasis
LR is the only curative treatment for CRLM. Recent advances in medical and surgical treatments have allowed for an important expansion in the limits of resectability and life expectancy in this population. 115 Only 30-40% of patients are candidates for LR at the time of disease presentation. 116 The main reason for precluding LR in patients with CRLM is insufficient liver remnant volume. For patients with insufficient liver remnant and no extrahepatic involvement, LT is becoming an option given that total hepatectomy will remove all viable disease.
LT for unresectable CRLM: A new hope
Initial reports on the use of LT for unresectable CRLM showed poor results. In 1991, Mühlbacher et al. reported their experience with 17 patients transplanted for CLRM, showing a 5-year OS rate of 12% and a 60% recurrence rate. 117 To improve outcomes they restricted LT to patients with negative lymph node disease in the primary specimen. 118 Penn published the results from a North American cohort. 5 This was a retrospective report of 637 patients with liver cancer; of those 8 patients underwent LT for CRLM. The recurrence rate was 70% and the 30-day mortality was 11%. Due to these poor results, in the early 1990s the use of LT for CLRM was abandoned. The use of LT for CRLM has regained momentum after the work of Hagness et al.. 119 Scandinavia is a region where the liver graft offer exceeds the demand. 120 In the SECA-I (SEcondary CAncer I) study, 21 patients underwent LT for CRLM. 119 The OS rate was 95% at 1 year and 60% at 5 years; the DFS rate was 35% at 1 year. Nineteen of 21 patients had tumour recurrence after a median 6 months (range 2-24 months). The most common site of recurrence was pulmonary (17/19 patients). In a subsequent publication, the authors assessed the recurrence patterns, showing a 57% 5-year postrecurrence survival. Patients with pulmonary-only metastasis, had slow growing recurrences despite immunosuppression, allowing for resection in 9/13 patients. 121 The remaining 8/17 recipients developed metastases in multiple sites, including hepatic recurrence, which was associated with the worst outcomes. 121 In the SECA-I study, the exclusion criteria were not very restrictive. The exclusion criteria were presence of extrahepatic disease and weight loss >10%. This approach allowed for the isolation of independent factors predicting worse OS: carcinoembryonic antigen (CEA) >80 ug/L, progression of the metastases under neoadjuvant chemotherapy, tumour diameter >5.5 cm, time interval from resection of the primary to LT <2 years. 119 An international consortium published the results of 12 patients with CRLM who underwent LT. 122 The OS rate was 50% with 6 patients having cancer recurrence after a median follow-up of 26 months. In accordance with previous studies, the most common site of recurrence was pulmonary.
LT for CRLM: beyond the initial enthusiasm As the concept of transplant benefit is gaining recognition over classic survival after transplantation or simplistic urgency criteria, 123, 124 LT for CLRM will likely find its place in future practice. However, before it becomes a recognised indication, definitive evidence is required to address a few outstanding issues:
It has to be proven that transplantation is superior to chemotherapy The SECA-I study provided encouraging evidence in favour of transplantation. Aiming to compare the results after LT to those seen after palliative chemotherapy, Dueland et al. compared the outcomes of their transplanted population (21 patients) to a matched cohort of patients who underwent palliative therapy. 125 They demonstrated improved 5-year OS in favour of LT (56%) compared to the chemotherapy (9%). 125 The cost-effectiveness of LT for CRLM in highly selected patients was recently shown. 126 Definitive confirmation of these retrospective findings will hopefully come from several ongoing trials. The SECA-III trial (NCT03494946) will compare LT to best multimodal alternative treatment (chemotherapy +/-locoregional therapies). The TRASNMET trial (NCT02597348) is a multicentric trial comparing LT for unresectable CRLM to chemotherapy only. Our centre is currently enrolling patients in a pilot study to assess the safety and effectiveness of neoadjuvant chemotherapy followed by LDLT for patients with unresectable CRLM (NCT02864485).
Patient selection has to be refined The population of patients enrolled into the SECA-I study was quite heterogeneous, helping with the identification of 4 factors associated with better survival (see above). Low CEA levels were also confirmed as a good prognostic factor by another study from an international consortium. 122 Moreover, a retrospective analysis using the SECA-I data was able to select a low-risk population (Oslo score 0-3) with a 5-year OS rate of 75%. 127 Another retrospective analysis on the SECA study data helped identify other predictors of post-transplant OS, such as the 'metabolic tumour volume' and 'the total lesional glycolysis' of the CLRM measured by 18 F-FDG PET/CT, 128 which could have a role in identifying patients with minor extrahepatic disease. 129 The recently published SECA-II trial showed that response to neoadjuvant chemotherapy is, in fact, important. Patients with a minimal response to chemotherapy of 10% had OS rates of 100%, 83% and 83% at 1-, 3-and 5-years , respectively. 130 The TRANSMET study contemplates additional criteria such as BRAF mutations, in order to exclude patients with aggressive tumour biology. This is also an exclusion criterion in the Toronto trial.
A standardised chemotherapy protocol has to be defined Thanks to modern neoadjuvant chemotherapy protocols, around 10-15% of patients with initially unresectable CRLM become candidates for LR. 131, 132 Therefore, it is clear that upfront chemotherapy should be offered to every patient potentially considered for LT, with the aim of conversion. In addition, as supported by the SECA-I and SECA-II trials, poor response to chemotherapy might be a criterion to identify high-risk candidates, who may not benefit from LT. Whether or not it is beneficial to administer post-transplant chemotherapy, instead, is a point yet to be explored. Patients enrolled in the SECA-I study were not given adjuvant (post-transplant) chemotherapy. The SECA-II/III and RAPID (see Table 3 ) trials do not have it as a formal requirement. With the exception of the SECA-II study, all the patients enrolled in these trials undergo liver transplant after multiple cycles of chemotherapy, some of them having already received second-and third-line treatments. In this context, the benefit of additional cycles may be marginal compared to their toxic effects, especially when involving small grafts (RAPID, LIVERT(W)OHEAL) and liver regeneration should not be impaired.
Patients enrolled in the TRASMET study receive limited post-transplant chemotherapy, while in the trial from Toronto, adjuvant standard-of-care chemotherapy is given. This last study will provide the more valuable information about the real benefit of post-transplant chemotherapy in the context of LT for CRLM, although only a randomisation would provide definitive evidence. Current ongoing trials in the field of LT for CRLM are summarised in Table 3 .
LT for CRLM: future perspectives
Coping with a potentially very high demand LT is a victim of its own success, with already accepted indications exhausting a very limited resource. If the ongoing trials confirmed a superior benefit of LT for unresectable CRLM over other treatments, organ allocation policy will have to deal with a considerable problem. Fortunately, most of the centres where LT for CRLM will become an option, are testing different strategies to mitigate this issue.
Some centres have proposed the use of auxiliary grafts in 2-staged procedures. The so-called RAPID procedure (Resection And Partial Liver Segment 2/3 Transplantation With Delayed Total Hepatectomy) It aims to perform a left lateral hepatectomy with a left lateral segment graft implantation. The rationale is to delay the completion of the total hepatectomy to allow the graft to grow. The first step is a limited segment 2-3 resection, which leaves the room for the auxiliary graft from a deceased donor. After reperfusion, the right portal vein is clamped and subsequently ligated if the pressure does not exceed 20 mmHg (if not, other measures are undertaken to lower the pressure: portal banding instead of complete interruption, splenic artery ligation, porto-caval shunting). The graft's volume increase is assessed regularly until liver/body weight ratio reaches 0.8. At that point patients undergo a second procedure, with totalisation of the hepatectomy. The LIVERT(W)OHEAL study (NCT03488953) from 2 German university hospitals, applies the RAPID concept to live donation.
Transplantation of patients with resectable CRLM R0 surgical resection is the gold standard treatment for patients with resectable CRLM. Recently, thanks to the advent of extremely effective chemotherapy protocols, even R1 resections can be considered curative if patients have positive response to systemic treatments. 134, 135 Interestingly, very large series on LR for CRLM showed 5-year OS rates of <40% for patients presenting with more than 3 metastases, 136 which is inferior to the overall 60% OS rate at 5 years of patients enrolled in the SECA-I study (median 8 metastases). On the other hand, the SECA-I population had very stable disease on chemotherapy, in contrast with the large case series on LR that included a broad heterogeneity of cases. The feeling is that some selected patients with borderline resectable disease and large tumour burden may benefit more from transplantation than from resection.
Neuroendocrine tumours
Liver metastases are common in neuroendocrine tumours (NETs) arising from the small intestine and pancreas. 137 (95% CI 2.4-23.0) for the control group compared to the LT group. 144 The use of time as a selection tool has also been reported. UNOS guidelines require patients with liver metastasis to be free of other sites of progression by 6 months before listing for LT. However, some agree that patients with indolent progression probably do not achieve the greatest survival benefit from LT. 145 It is also still not clear whether patients with more aggressive disease would benefit from LT given their lower probability of benefit from other therapies. Those are questions that need to be addressed by future research in the field.
Hepatic epithelioid haemangioendothelioma
Due to its rarity, the management of hepatic epithelioid haemangioendothelioma (HEHE) is still not well established. Furthermore, HEHE natural history varies from indolent to rapidly progressive disease. 146 For instance, the 5-year OS rate is reported to be 50% after LR and 30% with systemic chemotherapy. 147 150 In this series, the 5-and 10-year OS rates were 83% and 72%, respectively. More recently, this European experience was expanded by Lai et al.. 147 The 5-and 10-year OS rates were 77% and 74%, respectively. The risk factors for recurrence were presence of macrovascular invasion, waiting time greater than 120 days and presence of lymph nodal invasion. 147 A polish group reported a 3-year OS rate of 87% after LT.
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A study from the UNOS database on 110 transplanted patients with HEHE showed 5-year OS and DFS rates of 70% and 55%, respectively. 152 The best management of HEHE is still to be defined, but LT might offer a survival benefit for these patients compared to other therapies. Controversies around the best criteria for patient selection and preand post-LT management need to be addressed by further investigations. 
Conclusion
In conclusion, the field of LT is evolving rapidly to expand the indications of LT for patients with primary and secondary liver cancer. Fig. 1 presents a summary of the most important advances in LT for cancer. The current results are promising; however, caution should be taken when expanding LT criteria for cancer patients, to avoid compromising patients awaiting LT for chronic liver diseases. In the context of improvements in preoperative selection criteria, surgical technique and post-LT care, the dismal results from previous decades are not currently valid. Moreover, the better treatment of patients with chronic liver diseases (e.g. DAAs for HCV infection) will reduce the number of patients on the waiting list because of end-stage liver disease. Furthermore, techniques for donor pool expansion (e.g. donation after cardiac death, live donation, etc.) will likely improve the imbalance between the number of available grafts and the number of patients on the waiting list. In the era of transplant oncology, surgeons, hepatologists, radiation and medical oncologists should work towards the careful expansion of the use of LT for cancer patients.
Abbreviations
AFP, alpha-fetoprotein; AFP-L3, alpha-fetoprotein-lecithin 3; BMI, body mass index; CCA, cholangiocarcinoma; CEA, carcinoembryonic antigen; CRC, colorectal cancer; CRLM, colorectal liver metastasis; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DAA, direct-acting antiviral; DCP, des-gamma-carboxy prothrombin; DFS, disease-free-survival; GALAD, acronym for: Gender, Age, AFP-L3, AFP, DCP; HCC, hepatocellular carcinoma; LRT, locoregional therapy; LT, liver transplant; OS, overall survival; PD-1, programmed cell death protein 1; PDL-1, programmed deathligand 1; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolisation; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; TTD, total tumour diameter; TTV, total tumour volume; UCSF, University of California at San Francisco.
Financial support
